WOBURN, Mass., March 20 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) is shipping DyCE(TM) (Dynamic Contrast Enhancement), a new technology application, to users of the award-winning Maestro(TM) in vivo molecular imaging system. Customers can now generate all- optical anatomical images of mouse models in only a few minutes, saving time and enabling better time-resolved images of molecular probe distribution.
CRi has an exclusive commercialization agreement with Massachusetts General Hospital (MGH) for its DyCE application which received widespread acclaim when introduced at the recent Society of Molecular Imaging/Academy of Molecular Imaging joint conference for in vivo imaging. DyCE was also featured in the cover article in Nature Photonics in August of 2007.
“DyCE is a quantum leap forward for optical imaging, poised to revolutionize in vivo fluorescence imaging,” says James Mansfield, Director of Multispectral Imaging Systems at CRi. “Our customers can now produce anatomical images in record time and also save significant money versus conventional means.”
Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRi’s analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. This organ-specific imaging is possible, because organs have characteristic uptake or distribution patterns over time that can be ‘illuminated’ by the dye passing through, distinguishing them from other structures.
These in vivo anatomical maps can be overlaid co-registered with simultaneously acquired images of a targeted molecular probe to delineate the marker’s specific anatomical and physical location at any time point in the study.
“CRi is uniquely positioned to commercialize DyCE capitalizing on the combination of our advanced multispectral in vivo imaging systems and our industry-leading data analysis tools,” explains George Abe, CRi’s President and CEO.
“We are pleased to partner with the Massachusetts General Hospital in this endeavor and are excited to enable our customers to further advance their small animal imaging capabilities”, continued Abe.
CRi will be exhibiting the latest automated Maestro 2 system featuring DyCE along with CRi’s cellular imaging solutions at the Annual Meeting of the American Association for Cancer Research (AACR), April 12 to 16 (Booth 235). Attendees can make an appointment to meet with a sales or technical representative by e-mailing aacr@cri-inc.com or calling (Toll-Free US) 1-800- 383-7924.
CRi is a Boston-based biomedical imaging company providing innovative optical imaging solutions to our customers for more than 20 years. Our multidisciplinary team is dedicated to working with our academic and commercial customers to provide high-value solutions. We provide comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. CRi’s innovative solutions encompass sub-cellular, cellular and whole animal applications, and are being utilized around the world to enable breakthroughs in research, health and medicine.
www.cri-inc.comrnakatsuji@cri-inc.com
CONTACT: Ross Nakatsuji, CRi Marketing - Sales Group Leader,
+1-781-935-9099, ext. 177, Cell +1-781-405-4000, rnakatsuji@cri-inc.com
Web site: http://www.cri-inc.com/
